A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer, Breast|Cancer, Lung|Cancer of Pancreas|Cancer of Esophagus|Cancer Colorectal
Interventions: DRUG: CBP-1019
Sponsor: Coherent Biopharma (Hefei) Co., Ltd.